Helix Biomedic

Helix BioMedix is a U.S.-based dermatology-focused biopharmaceutical company developing peptide-based therapeutics and related skin health products. The company is currently centered on HB4208, a preclinical DNA damage response enzyme program for xeroderma pigmentosum, an ultra-rare genetic dermatologic disorder characterized by impaired repair of UV-induced DNA damage. In addition to its rare disease program, Helix BioMedix maintains a legacy portfolio and proprietary library of patented bioactive peptides with potential applications across pharmaceutical, OTC, aesthetic, and personal care markets. The company has historically emphasized peptide discovery, licensing, and commercialization opportunities in dermatology and skin health.